Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$1.16
-3.3%
$1.22
$0.84
$2.03
$44.23M0.99118,426 shs13,256 shs
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$23.53
-3.0%
$28.76
$9.44
$36.25
$1.20B2.871.04 million shs453,265 shs
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$10.25
$10.25
$1.40
$10.44
$744.95M-0.331.32 million shsN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$10.60
+0.3%
$11.42
$8.20
$18.24
$379.90M1.19273,719 shs171,996 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$1.70
-2.3%
$2.03
$1.62
$5.70
$115.97M-0.36292,039 shs181,017 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
+7.21%+7.21%-0.83%+9.17%-25.63%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-2.26%-4.15%-27.83%+27.10%+15.37%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00%0.00%0.00%+1.89%+606.90%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-3.82%-1.03%-6.87%+1.54%-21.41%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-7.45%+0.58%-14.71%-26.89%-59.63%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.6485 of 5 stars
3.50.00.00.03.23.31.3
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.9635 of 5 stars
4.51.00.00.02.73.30.0
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
1.3281 of 5 stars
3.51.00.00.00.62.50.6
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3.319 of 5 stars
4.50.00.00.02.42.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
3.00
Buy$7.00503.45% Upside
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
3.00
Buy$44.2287.94% Upside
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
2.38
Hold$13.0427.18% Upside
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
3.00
Buy$30.33186.16% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3.00
Buy$13.50694.12% Upside

Current Analyst Ratings

Latest ITOS, BOLT, FDMT, VOR, and GRCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
4/15/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$35.00 ➝ $40.00
4/15/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
4/1/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$70.00 ➝ $63.00
4/1/2024
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $58.00
3/22/2024
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
3/22/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$12.00
3/21/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
3/21/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$17.00 ➝ $15.00
3/21/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
3/21/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.50
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.88M5.61N/AN/A$2.97 per share0.39
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$20.72M58.10N/AN/A$7.20 per share3.27
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$60K12,415.83N/AN/A$2.95 per share3.47
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$12.60M30.15N/AN/A$16.08 per share0.66
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$69.20M-$1.83N/AN/AN/A-878.58%-51.18%-37.81%5/9/2024 (Estimated)
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$100.84M-$2.66N/AN/AN/A-436.30%-34.14%-31.07%5/8/2024 (Estimated)
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$112.64M-$3.15N/AN/AN/AN/A-18.40%-16.22%5/8/2024 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$1.76N/AN/AN/AN/AN/AN/A5/9/2024 (Estimated)

Latest ITOS, BOLT, FDMT, VOR, and GRCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$0.47-$0.47N/A-$0.47$1.97 million$2.09 million
3/20/2024Q4 2023
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.49-$0.39+$0.10-$0.39N/AN/A
3/6/202412/31/2023
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$1.03-$0.85+$0.18-$0.85$37.41 millionN/A
2/29/2024Q4 2023
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.68-$0.77-$0.09-$0.77$4.67 million($0.02) million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.15
5.17
5.17
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
15.65
15.65
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.02
7.73
7.73
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/A
13.76
13.76
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
10038.13 million27.30 millionNot Optionable
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
14751.16 million45.68 millionOptionable
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
31472.68 million52.33 millionOptionable
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
15735.84 million32.19 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
16868.22 million59.76 millionNot Optionable

ITOS, BOLT, FDMT, VOR, and GRCL Headlines

SourceHeadline
Vor Biopharma (NYSE:VOR) Receives Outperform Rating from WedbushVor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush
americanbankingnews.com - April 24 at 5:20 AM
Puretech Health gets grant for treatment of acute myeloid leukemia using genetically engineered cellsPuretech Health gets grant for treatment of acute myeloid leukemia using genetically engineered cells
pharmaceutical-technology.com - April 23 at 8:16 PM
Vor Biopharma (NYSE:VOR) Earns "Outperform" Rating from WedbushVor Biopharma (NYSE:VOR) Earns "Outperform" Rating from Wedbush
marketbeat.com - April 23 at 1:48 PM
TriLink BioTechnologies® kündigt neue Anlage in San Diego zur mRNA-Produktion von Arzneimittelwirkstoffen in der Spätphase anTriLink BioTechnologies® kündigt neue Anlage in San Diego zur mRNA-Produktion von Arzneimittelwirkstoffen in der Spätphase an
joplinglobe.com - April 20 at 8:41 PM
Vor Biopharma (NYSE:VOR) Trading Down 5.3%Vor Biopharma (NYSE:VOR) Trading Down 5.3%
americanbankingnews.com - April 16 at 1:52 AM
Buy Rating Affirmed for Vor Biopharma on Clinical Progress and Market PotentialBuy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potential
markets.businessinsider.com - April 13 at 12:43 AM
Seven diseases CRISPR technology could cureSeven diseases CRISPR technology could cure
labiotech.eu - April 4 at 7:22 PM
Why You Shouldnt Bet Against Vor Biopharma (VOR) StockWhy You Shouldn't Bet Against Vor Biopharma (VOR) Stock
zacks.com - April 4 at 9:36 AM
Vor Bio to Participate in Upcoming Investor ConferencesVor Bio to Participate in Upcoming Investor Conferences
globenewswire.com - April 1 at 8:00 AM
Heres Why Were Watching Vor Biopharmas (NASDAQ:VOR) Cash Burn SituationHere's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
finance.yahoo.com - March 29 at 7:12 AM
The Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessThe Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
investorplace.com - March 28 at 2:28 PM
Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)
markets.businessinsider.com - March 26 at 1:44 AM
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)
markets.businessinsider.com - March 22 at 3:59 PM
Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
finanznachrichten.de - March 22 at 5:21 AM
Analysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)Analysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)
markets.businessinsider.com - March 21 at 7:20 PM
Vor Biopharma: Q4 Earnings InsightsVor Biopharma: Q4 Earnings Insights
benzinga.com - March 20 at 9:49 PM
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results  and Provides Company UpdateVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
finance.yahoo.com - March 20 at 4:49 PM
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
globenewswire.com - March 20 at 4:05 PM
Intellia Therapeutics doses first patient in pivotal in vivo CRISPR trialIntellia Therapeutics doses first patient in pivotal in vivo CRISPR trial
msn.com - March 19 at 5:15 PM
VOR Apr 2024 5.000 callVOR Apr 2024 5.000 call
finance.yahoo.com - March 16 at 11:47 PM
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 5 at 4:01 PM
Vor Bio to Participate in Upcoming Investor ConferencesVor Bio to Participate in Upcoming Investor Conferences
globenewswire.com - March 4 at 8:00 AM
Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the companyInstitutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company
finance.yahoo.com - February 17 at 9:46 AM
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
finance.yahoo.com - February 15 at 5:49 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bolt Biotherapeutics logo

Bolt Biotherapeutics

NASDAQ:BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
4D Molecular Therapeutics logo

4D Molecular Therapeutics

NASDAQ:FDMT
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Gracell Biotechnologies logo

Gracell Biotechnologies

NASDAQ:GRCL
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.
iTeos Therapeutics logo

iTeos Therapeutics

NASDAQ:ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Vor Biopharma logo

Vor Biopharma

NYSE:VOR
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.